Literature DB >> 16533529

Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.

Felipe Lorenzo1, Kazuhiro Nishii, Fumihiko Monma, Shogo Kuwagata, Eiji Usui, Hiroshi Shiku.   

Abstract

The progenitor cells of myelodysplastic syndrome (MDS) are thought to undergo a multistep process during their transformation into overt acute leukemia. In this study, the role of mutation of the KIT gene in the extracellular membrane, juxtamembrane and tyrosine kinase domains was investigated in 75 patients with MDS or MDS-derived leukemia (MDS-AML). Mutation was detected in 2 of 15 (13.3%) patients with refractory anemia with excess blasts transformation (RAEB-T), in 1 of 15 (6.6%) patients with chronic myelomonocytic leukemia (CMML), and in 5 of 26 (19.2%) patients with MDS-AML. However, no mutation was found in any of the nine patients with refractory anemia (RA) or the 10 patients with refractory anemia with excess blasts (RAEB). Of the mutations, five patients had changes at the same codon in tyrosine kinase domain, Asp816, while the remainder had unique mutations. These observations suggest that KIT gene mutations identified in the advanced stage of MDS, and genetic abnormality in the KIT gene, particularly at codon 816, might be additional events that contribute to the progression of MDS to AML.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533529     DOI: 10.1016/j.leukres.2006.02.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

Authors:  Daniel C Link; Ghada Kunter; Yumi Kasai; Yu Zhao; Tracie Miner; Michael D McLellan; Rhonda E Ries; Deepak Kapur; Rakesh Nagarajan; David C Dale; Audrey Anna Bolyard; Laurence A Boxer; Karl Welte; Cornelia Zeidler; Jean Donadieu; Christine Bellanné-Chantelot; James W Vardiman; Michael A Caligiuri; Clara D Bloomfield; John F DiPersio; Michael H Tomasson; Timothy A Graubert; Peter Westervelt; Mark Watson; William Shannon; Jack Baty; Elaine R Mardis; Richard K Wilson; Timothy J Ley
Journal:  Blood       Date:  2007-05-09       Impact factor: 22.113

2.  RNAi screen for rapid therapeutic target identification in leukemia patients.

Authors:  Jeffrey W Tyner; Michael W Deininger; Marc M Loriaux; Bill H Chang; Jason R Gotlib; Stephanie G Willis; Heidi Erickson; Tibor Kovacsovics; Thomas O'Hare; Michael C Heinrich; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

Review 3.  Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Authors:  Srdan Verstovsek
Journal:  Leuk Res       Date:  2008-11-14       Impact factor: 3.156

4.  Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Authors:  Jeffrey W Tyner; Wayne F Yang; Armand Bankhead; Guang Fan; Luke B Fletcher; Jade Bryant; Jason M Glover; Bill H Chang; Stephen E Spurgeon; William H Fleming; Tibor Kovacsovics; Jason R Gotlib; Stephen T Oh; Michael W Deininger; Christian Michel Zwaan; Monique L Den Boer; Marry M van den Heuvel-Eibrink; Thomas O'Hare; Brian J Druker; Marc M Loriaux
Journal:  Cancer Res       Date:  2012-10-18       Impact factor: 12.701

5.  Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis.

Authors:  Jeffrey W Craig; Robert P Hasserjian; Annette S Kim; Jon C Aster; Geraldine S Pinkus; Jason L Hornick; David P Steensma; R Coleman Lindsley; Daniel J DeAngelo; Elizabeth A Morgan
Journal:  Mod Pathol       Date:  2020-01-02       Impact factor: 7.842

6.  Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.

Authors:  Teresa Kaserer; Julian Blagg
Journal:  Cell Chem Biol       Date:  2018-08-23       Impact factor: 8.116

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.